BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 37019737)

  • 1. Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.
    Haghnejad V; Muller M; Blaise L; Gerolami R; Bouattour M; Assenat E; Manfredi S; Peron JM; Burcheri-Curatolo A; Lopez A; Ressiot E; Nahon P; Bronowicki JP
    Dig Liver Dis; 2023 Jul; 55(7):938-944. PubMed ID: 37019737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of response to atezolizumab + bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial.
    Salem R; Li D; Sommer N; Hernandez S; Verret W; Ding B; Lencioni R
    Cancer Med; 2021 Aug; 10(16):5437-5447. PubMed ID: 34189869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Aoki T; Kuroda H; Yata Y; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y; Kudo M;
    Liver Int; 2024 Jan; 44(1):113-124. PubMed ID: 37789669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of anti-PD-1/PD-L1 antibodies combined with VEGF receptor tyrosine kinase inhibitors versus bevacizumab in unresectable hepatocellular carcinoma.
    Zeng H; Xu Q; Wang J; Xu X; Luo J; Zhang L; Luo C; Ying J; Li J
    Front Immunol; 2023; 14():1073133. PubMed ID: 36756114
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
    Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
    Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of first-line systemic therapy with atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    Tada T; Kumada T; Hiraoka A; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Tada F; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Kosaka H; Naganuma A; Matono T; Koizumi Y; Nakamura S; Kaibori M; Iijima H; Hiasa Y;
    J Gastroenterol Hepatol; 2023 Aug; 38(8):1389-1397. PubMed ID: 37231943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher objective responses by hepatic arterial infusion chemotherapy following atezolizumab and bevacizumab failure than when used as initial therapy in hepatocellular carcinoma: a retrospective study.
    Yoo JS; Kim JH; Cho HS; Han JW; Jang JW; Choi JY; Yoon SK; Kim S; Oh JS; Chun HJ; Sung PS
    Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38678485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.
    Cheng AL; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Lim HY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Ma N; Nicholas A; Wang Y; Li L; Zhu AX; Finn RS
    J Hepatol; 2022 Apr; 76(4):862-873. PubMed ID: 34902530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC.
    Yang J; Choi J; Choi WM; Kim KM; Lee HC; Shim JH
    Liver Int; 2024 Apr; 44(4):907-919. PubMed ID: 38291863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma.
    Kawamura Y; Kobayashi M; Shindoh J; Matsumura M; Okubo S; Muraishi N; Fujiyama S; Hosaka T; Saitoh S; Sezaki H; Akuta N; Suzuki F; Suzuki Y; Ikeda K; Arase Y; Hashimoto M; Kumada H
    Oncology; 2022; 100(6):320-330. PubMed ID: 35231914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.
    Wang K; Xiang YJ; Yu HM; Cheng YQ; Liu ZH; Zhong JY; Feng S; Ni QZ; Zhu HF; Pan WW; Li JJ; Liang C; Zhou HK; Meng Y; Lau WY; Cheng SQ
    Front Immunol; 2023; 14():1107542. PubMed ID: 36875125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of atezolizumab plus bevacizumab combination therapy for hepatocellular carcinoma using contrast-enhanced ultrasonography.
    Uchikawa S; Kawaoka T; Fujino H; Ono A; Nakahara T; Murakami E; Yamauchi M; Miki D; Imamura M; Aikata H
    J Med Ultrason (2001); 2023 Jan; 50(1):57-62. PubMed ID: 36169740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects on survival of the adverse event of atezolizumab plus bevacizumab for hepatocellular carcinoma: a multicenter study by the Japan Red Cross Liver Study Group.
    Takaki S; Kurosaki M; Mori N; Tsuji K; Ochi H; Marusawa H; Nakamura S; Tada T; Narita R; Uchida Y; Akahane T; Kondo M; Kusakabe A; Furuta K; Kobashi H; Arai H; Nonogi M; Tamada T; Hasebe C; Ogawa C; Sato T; Tamaki N; Yasui Y; Tsuchiya K; Izumi N
    Invest New Drugs; 2023 Apr; 41(2):340-349. PubMed ID: 36995548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
    Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
    Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
    Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J;
    Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of hepatocellular carcinoma with "pseudoprogression" followed by complete response to atezolizumab plus bevacizumab.
    Odagiri N; Tamori A; Kotani K; Motoyama H; Kawamura E; Hagihara A; Fujii H; Uchida-Kobayashi S; Enomoto M; Kawada N
    Clin J Gastroenterol; 2023 Jun; 16(3):392-396. PubMed ID: 36739366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.